ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

Christophe Guignabert; Frances de Man; Marc Lombès

doi:10.1183/13993003.00848-2018

Journal articles

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

Christophe Guignabert ^{1, 2} Frances de Man ³ Marc Lombès ^{1, 4}

1 Université Paris-Saclay

2 Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique

3 VU University Medical Center [Amsterdam]

4 Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique

Abstract : no abstract

Domain :

Life Sciences [q-bio]

Life Sciences [q-bio] / Human health and pathology

Life Sciences [q-bio] / Human health and pathology / Pulmonology and respiratory tract

Life Sciences [q-bio] / Human health and pathology / Endocrinology and metabolism

Life Sciences [q-bio] / Human health and pathology / Cardiology and cardiovascular system

Life Sciences [q-bio] / Human health and pathology / Urology and Nephrology

Life Sciences [q-bio] / Santé publique et épidémiologie

Complete list of metadatas

https://www.hal.inserm.fr/inserm-02582393
Contributor : Christophe Guignabert <>
Submitted on : Thursday, May 14, 2020 - 9:41:08 PM
Last modification on : Saturday, May 16, 2020 - 3:31:10 AM

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

Links full text

Identifiers

Collections

Citation

Export

Metrics

8

Contact

Informations

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

8

Contact

Informations